Home  /   Products  /   Diabetes  /   Insulin soluble human genetically engineered (Rinsulin R) subcutaneous 100 IU/ml 3 ml – [5 cartridges]
Insulin soluble human genetically engineered (Rinsulin R) subcutaneous 100 IU/ml 3 ml - [5 cartridges]

Insulin soluble human genetically engineered (Rinsulin R) subcutaneous 100 IU/ml 3 ml – [5 cartridges]

$45.54

Short acting human insulin

SKU: 62720 Category:

Description

Rinsulin R Pharmacodynamics
Rinsulin® P is a human insulin produced using recombinant DNA technology. Short-acting insulin.
It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, which stimulates intracellular processes, including synthesis of several key enzymes (hexokinase, pyruvate kinase, glycogen synthase etc.). Decrease of glucose content in blood is caused by increase of its intracellular transport, intensification of absorption and assimilation by tissues, stimulation of lipogenesis, glycogenogenesis, decrease of glucose production rate by liver, etc.
The duration of action of insulin drugs is mainly due to the absorption rate, which depends on several factors (e.g., the dose, route and place of administration), and therefore the action profile of insulin is subject to significant fluctuations, both in different people and in the same person.
On average, after subcutaneous administration Rinsulin® P begins to act after 30 minutes, maximum effect develops between 1 and 3 hours, the duration of action is 8 hours.

 

Indications
– Type 1 diabetes mellitus;
– Diabetes mellitus type 2: stage of resistance to oral hypoglycemic agents, partial resistance to these drugs (during combined therapy), intercurrent diseases;
– Diabetes mellitus type 2 in pregnant women;
– Emergency conditions in patients with diabetes mellitus, accompanied with decompensation of carbohydrate metabolism.

 

Contraindications .
– Hypersensitivity to insulin or any of the components of the drug;
– hypoglycemia.
Pregnancy and lactation:
There are no restrictions on the treatment of diabetes with insulin during pregnancy, since insulin does not penetrate the placental barrier. Intensified treatment of diabetes mellitus is necessary during pregnancy planning and during pregnancy. The need for insulin usually decreases in the first trimester of pregnancy and gradually increases in the second and third trimesters.
During childbirth and immediately after, the need for insulin may decrease dramatically. Shortly after delivery, insulin requirements quickly return to pre-pregnancy levels.
There are no restrictions on the treatment of diabetes with insulin during breastfeeding. However, it may be necessary to reduce the dose of insulin, so close monitoring for several months until the need for insulin is stabilized.

 

Dosage and administration method

 

  • The drug is intended for subcutaneous, intramuscular and intravenous administration.
  • The dose and route of administration of the drug are determined by the physician individually for each case on the basis of blood glucose concentrations.
  • The average daily dose of the drug ranges from 0.5 to 1 IU/kg of body weight (depends on the individual characteristics of the patient and the blood glucose concentration).
  • The drug is administered 30 minutes before a meal or snack containing carbohydrates.
  • The temperature of injected insulin must correspond to room temperature.
  • When monotherapy with the drug, the frequency of administration is 3 times a day (if necessary, up to 5-6 times a day). If the daily dose is more than 0.6 IU/kg, the drug must be given as 2 or more injections in different parts of the body.
  • The drug is usually injected subcutaneously into the anterior abdominal wall. Injections can also be made in the thigh, buttock or shoulder at the projection of the deltoid muscle.
  • It is necessary to change the injection sites within the anatomical area in order to prevent the development of lipodystrophy. When injecting insulin subcutaneously, care must be taken not to get into a blood vessel during injection. After injection, the injection site should not be massaged. Patients must be trained in the correct use of the insulin injection device.
  • Intramuscularly and intravenously the drug may be administered only under the supervision of a physician.
  • Vials may be used only if their contents are a clear colorless liquid without visible particles. Do not use the drug if there is sediment in the solution. Rinsulin® P is short-acting insulin and is usually used in combination with medium-acting insulin (Rinsulin® NPC).
  • The product in use may be stored at room temperature (15 to 25 °C) for up to 28 days.

Related products